nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ABCC1—Dactinomycin—peripheral nervous system neoplasm	0.0627	0.143	CbGbCtD
Vandetanib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0605	0.138	CbGbCtD
Vandetanib—ABCC1—Epirubicin—peripheral nervous system neoplasm	0.0454	0.104	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.042	0.0958	CbGbCtD
Vandetanib—ABCC1—Vincristine—peripheral nervous system neoplasm	0.0386	0.0882	CbGbCtD
Vandetanib—ABCC1—Etoposide—peripheral nervous system neoplasm	0.0354	0.0808	CbGbCtD
Vandetanib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0258	0.059	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—peripheral nervous system neoplasm	0.0241	0.0551	CbGbCtD
Vandetanib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0241	0.055	CbGbCtD
Vandetanib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0237	0.0541	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0161	0.0369	CbGbCtD
Vandetanib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0131	0.0299	CbGbCtD
Vandetanib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0122	0.0278	CbGbCtD
Vandetanib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00558	0.0127	CbGbCtD
Vandetanib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00512	0.0117	CbGbCtD
Vandetanib—LTK—tongue—peripheral nervous system neoplasm	0.00459	0.078	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00349	0.00797	CbGbCtD
Vandetanib—Afatinib—ERBB2—peripheral nervous system neoplasm	0.00347	0.348	CrCbGaD
Vandetanib—Gefitinib—CHEK2—peripheral nervous system neoplasm	0.00181	0.182	CrCbGaD
Vandetanib—Bosutinib—CHEK2—peripheral nervous system neoplasm	0.00179	0.18	CrCbGaD
Vandetanib—EPHA5—trigeminal ganglion—peripheral nervous system neoplasm	0.00169	0.0287	CbGeAlD
Vandetanib—Bosutinib—ALK—peripheral nervous system neoplasm	0.00159	0.16	CrCbGaD
Vandetanib—TYRO3—brainstem—peripheral nervous system neoplasm	0.0015	0.0254	CbGeAlD
Vandetanib—RIPK2—trigeminal ganglion—peripheral nervous system neoplasm	0.0013	0.0221	CbGeAlD
Vandetanib—VEGFA—trigeminal ganglion—peripheral nervous system neoplasm	0.0013	0.022	CbGeAlD
Vandetanib—FMO1—trigeminal ganglion—peripheral nervous system neoplasm	0.00129	0.0219	CbGeAlD
Vandetanib—IRAK4—trigeminal ganglion—peripheral nervous system neoplasm	0.00127	0.0215	CbGeAlD
Vandetanib—STK35—brainstem—peripheral nervous system neoplasm	0.00125	0.0212	CbGeAlD
Vandetanib—RIPK2—parotid gland—peripheral nervous system neoplasm	0.00122	0.0208	CbGeAlD
Vandetanib—FMO1—parotid gland—peripheral nervous system neoplasm	0.00122	0.0206	CbGeAlD
Vandetanib—IRAK4—parotid gland—peripheral nervous system neoplasm	0.0012	0.0203	CbGeAlD
Vandetanib—MKNK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00117	0.0198	CbGeAlD
Vandetanib—LCK—trigeminal ganglion—peripheral nervous system neoplasm	0.00115	0.0196	CbGeAlD
Vandetanib—RET—trigeminal ganglion—peripheral nervous system neoplasm	0.00115	0.0196	CbGeAlD
Vandetanib—AXL—trigeminal ganglion—peripheral nervous system neoplasm	0.00115	0.0195	CbGeAlD
Vandetanib—SLK—trigeminal ganglion—peripheral nervous system neoplasm	0.00111	0.0188	CbGeAlD
Vandetanib—FYN—trigeminal ganglion—peripheral nervous system neoplasm	0.00107	0.0183	CbGeAlD
Vandetanib—MAP4K5—trigeminal ganglion—peripheral nervous system neoplasm	0.00105	0.0178	CbGeAlD
Vandetanib—TEK—trigeminal ganglion—peripheral nervous system neoplasm	0.00105	0.0178	CbGeAlD
Vandetanib—FMO3—parotid gland—peripheral nervous system neoplasm	0.00105	0.0178	CbGeAlD
Vandetanib—SLK—parotid gland—peripheral nervous system neoplasm	0.00104	0.0177	CbGeAlD
Vandetanib—EPHB6—trigeminal ganglion—peripheral nervous system neoplasm	0.001	0.017	CbGeAlD
Vandetanib—MAP4K5—parotid gland—peripheral nervous system neoplasm	0.000991	0.0168	CbGeAlD
Vandetanib—YES1—trigeminal ganglion—peripheral nervous system neoplasm	0.00097	0.0165	CbGeAlD
Vandetanib—STK10—trigeminal ganglion—peripheral nervous system neoplasm	0.000961	0.0163	CbGeAlD
Vandetanib—EPHA8—cerebellum—peripheral nervous system neoplasm	0.000954	0.0162	CbGeAlD
Vandetanib—FYN—brainstem—peripheral nervous system neoplasm	0.000951	0.0162	CbGeAlD
Vandetanib—EPHB6—parotid gland—peripheral nervous system neoplasm	0.000947	0.0161	CbGeAlD
Vandetanib—ERBB3—Podofilox—Etoposide—peripheral nervous system neoplasm	0.000933	0.168	CbGdCrCtD
Vandetanib—YES1—parotid gland—peripheral nervous system neoplasm	0.000915	0.0155	CbGeAlD
Vandetanib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000858	0.0146	CbGeAlD
Vandetanib—KDR—trigeminal ganglion—peripheral nervous system neoplasm	0.000858	0.0146	CbGeAlD
Vandetanib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.00081	0.0137	CbGeAlD
Vandetanib—KDR—parotid gland—peripheral nervous system neoplasm	0.00081	0.0137	CbGeAlD
Vandetanib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.00076	0.0129	CbGeAlD
Vandetanib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000743	0.0126	CbGeAlD
Vandetanib—EPHA5—cerebellum—peripheral nervous system neoplasm	0.000738	0.0125	CbGeAlD
Vandetanib—TYRO3—cerebellum—peripheral nervous system neoplasm	0.000738	0.0125	CbGeAlD
Vandetanib—BMPR1B—cerebellum—peripheral nervous system neoplasm	0.000723	0.0123	CbGeAlD
Vandetanib—PLK4—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000715	0.129	CbGdCrCtD
Vandetanib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000701	0.0119	CbGeAlD
Vandetanib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000662	0.0112	CbGeAlD
Vandetanib—ERBB3—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.000642	0.116	CbGdCrCtD
Vandetanib—FLT3—cerebellum—peripheral nervous system neoplasm	0.000627	0.0107	CbGeAlD
Vandetanib—ABL1—parotid gland—peripheral nervous system neoplasm	0.000625	0.0106	CbGeAlD
Vandetanib—STK35—cerebellum—peripheral nervous system neoplasm	0.000615	0.0104	CbGeAlD
Vandetanib—ABL2—cerebellum—peripheral nervous system neoplasm	0.000599	0.0102	CbGeAlD
Vandetanib—ABL1—brainstem—peripheral nervous system neoplasm	0.000586	0.00995	CbGeAlD
Vandetanib—EGFR—cerebellum—peripheral nervous system neoplasm	0.000585	0.00993	CbGeAlD
Vandetanib—RIPK2—cerebellum—peripheral nervous system neoplasm	0.000567	0.00962	CbGeAlD
Vandetanib—VEGFA—cerebellum—peripheral nervous system neoplasm	0.000565	0.0096	CbGeAlD
Vandetanib—IRAK4—cerebellum—peripheral nervous system neoplasm	0.000553	0.0094	CbGeAlD
Vandetanib—ERBB3—cerebellum—peripheral nervous system neoplasm	0.000542	0.00921	CbGeAlD
Vandetanib—MKNK1—cerebellum—peripheral nervous system neoplasm	0.000509	0.00865	CbGeAlD
Vandetanib—RET—cerebellum—peripheral nervous system neoplasm	0.000503	0.00854	CbGeAlD
Vandetanib—AXL—cerebellum—peripheral nervous system neoplasm	0.000501	0.00851	CbGeAlD
Vandetanib—Afatinib—ABCB1—peripheral nervous system neoplasm	0.000499	0.0501	CrCbGaD
Vandetanib—SLK—cerebellum—peripheral nervous system neoplasm	0.000482	0.00819	CbGeAlD
Vandetanib—ABCC1—parotid gland—peripheral nervous system neoplasm	0.000476	0.00808	CbGeAlD
Vandetanib—FYN—cerebellum—peripheral nervous system neoplasm	0.000469	0.00796	CbGeAlD
Vandetanib—TEK—cerebellum—peripheral nervous system neoplasm	0.000458	0.00778	CbGeAlD
Vandetanib—MAP4K5—cerebellum—peripheral nervous system neoplasm	0.000458	0.00778	CbGeAlD
Vandetanib—EPHB6—cerebellum—peripheral nervous system neoplasm	0.000438	0.00744	CbGeAlD
Vandetanib—YES1—cerebellum—peripheral nervous system neoplasm	0.000423	0.00719	CbGeAlD
Vandetanib—STK10—cerebellum—peripheral nervous system neoplasm	0.000419	0.00712	CbGeAlD
Vandetanib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000418	0.00709	CbGeAlD
Vandetanib—SRC—cerebellum—peripheral nervous system neoplasm	0.000407	0.00691	CbGeAlD
Vandetanib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000394	0.00669	CbGeAlD
Vandetanib—MAP2K5—cerebellum—peripheral nervous system neoplasm	0.000374	0.00636	CbGeAlD
Vandetanib—KDR—cerebellum—peripheral nervous system neoplasm	0.000374	0.00636	CbGeAlD
Vandetanib—PLK4—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000373	0.0674	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000373	0.0674	CbGdCrCtD
Vandetanib—Erlotinib—ABCB1—peripheral nervous system neoplasm	0.000352	0.0354	CrCbGaD
Vandetanib—PLK4—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.0623	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.0623	CbGdCrCtD
Vandetanib—PDGFRB—cerebellum—peripheral nervous system neoplasm	0.000324	0.0055	CbGeAlD
Vandetanib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000314	0.0566	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000314	0.0566	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000314	0.0566	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.0524	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.0524	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.0524	CbGdCrCtD
Vandetanib—ABL1—cerebellum—peripheral nervous system neoplasm	0.000289	0.00491	CbGeAlD
Vandetanib—Gefitinib—ABCB1—peripheral nervous system neoplasm	0.00022	0.0222	CrCbGaD
Vandetanib—ABCC1—cerebellum—peripheral nervous system neoplasm	0.00022	0.00374	CbGeAlD
Vandetanib—Bosutinib—ABCB1—peripheral nervous system neoplasm	0.000217	0.0218	CrCbGaD
Vandetanib—ABCG2—cerebellum—peripheral nervous system neoplasm	0.000182	0.00309	CbGeAlD
Vandetanib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000144	0.000549	CcSEcCtD
Vandetanib—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000143	0.000548	CcSEcCtD
Vandetanib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000143	0.000547	CcSEcCtD
Vandetanib—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000547	CcSEcCtD
Vandetanib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000143	0.000547	CcSEcCtD
Vandetanib—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000547	CcSEcCtD
Vandetanib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000143	0.000546	CcSEcCtD
Vandetanib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000143	0.000546	CcSEcCtD
Vandetanib—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000143	0.000546	CcSEcCtD
Vandetanib—Constipation—Vincristine—peripheral nervous system neoplasm	0.000142	0.000545	CcSEcCtD
Vandetanib—Pain—Vincristine—peripheral nervous system neoplasm	0.000142	0.000545	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.000545	CcSEcCtD
Vandetanib—Rash—Melphalan—peripheral nervous system neoplasm	0.000142	0.000543	CcSEcCtD
Vandetanib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000142	0.000542	CcSEcCtD
Vandetanib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000141	0.000541	CcSEcCtD
Vandetanib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000539	CcSEcCtD
Vandetanib—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000141	0.000538	CcSEcCtD
Vandetanib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000536	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00014	0.000535	CcSEcCtD
Vandetanib—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000526	CcSEcCtD
Vandetanib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000137	0.000523	CcSEcCtD
Vandetanib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000137	0.000523	CcSEcCtD
Vandetanib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000136	0.000522	CcSEcCtD
Vandetanib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000136	0.000521	CcSEcCtD
Vandetanib—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000521	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000519	CcSEcCtD
Vandetanib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000135	0.000518	CcSEcCtD
Vandetanib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000135	0.000518	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000518	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000134	0.000513	CcSEcCtD
Vandetanib—Infection—Etoposide—peripheral nervous system neoplasm	0.000134	0.000513	CcSEcCtD
Vandetanib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000134	0.000512	CcSEcCtD
Vandetanib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000134	0.000511	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.00051	CcSEcCtD
Vandetanib—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000509	CcSEcCtD
Vandetanib—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000509	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000506	CcSEcCtD
Vandetanib—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000132	0.000506	CcSEcCtD
Vandetanib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000132	0.000505	CcSEcCtD
Vandetanib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000132	0.000504	CcSEcCtD
Vandetanib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000132	0.000504	CcSEcCtD
Vandetanib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000131	0.000502	CcSEcCtD
Vandetanib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000131	0.000501	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000499	CcSEcCtD
Vandetanib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000499	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000496	CcSEcCtD
Vandetanib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000128	0.00049	CcSEcCtD
Vandetanib—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000489	CcSEcCtD
Vandetanib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000127	0.000488	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000487	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000127	0.000486	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000482	CcSEcCtD
Vandetanib—Pain—Cisplatin—peripheral nervous system neoplasm	0.000126	0.000482	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.00048	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000476	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000476	CcSEcCtD
Vandetanib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000124	0.000474	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000473	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000471	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000471	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000123	0.00047	CcSEcCtD
Vandetanib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000122	0.000468	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000464	CcSEcCtD
Vandetanib—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000121	0.000463	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000461	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.00012	0.00046	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.00012	0.00046	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000459	CcSEcCtD
Vandetanib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000119	0.000457	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000456	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000453	CcSEcCtD
Vandetanib—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000453	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000118	0.000453	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000453	CcSEcCtD
Vandetanib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000118	0.000452	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000118	0.00045	CcSEcCtD
Vandetanib—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000117	0.00045	CcSEcCtD
Vandetanib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000117	0.000449	CcSEcCtD
Vandetanib—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000446	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000116	0.000445	CcSEcCtD
Vandetanib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000116	0.000445	CcSEcCtD
Vandetanib—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000116	0.000445	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000442	CcSEcCtD
Vandetanib—Pain—Etoposide—peripheral nervous system neoplasm	0.000115	0.000441	CcSEcCtD
Vandetanib—Constipation—Etoposide—peripheral nervous system neoplasm	0.000115	0.000441	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000441	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000441	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.00044	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.00044	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000437	CcSEcCtD
Vandetanib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000114	0.000437	CcSEcCtD
Vandetanib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000114	0.000436	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000435	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000432	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.00043	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000429	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000428	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000426	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000425	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000425	CcSEcCtD
Vandetanib—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000111	0.000423	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000422	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00011	0.000422	CcSEcCtD
Vandetanib—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00011	0.000421	CcSEcCtD
Vandetanib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00011	0.00042	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.00042	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.00042	CcSEcCtD
Vandetanib—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000109	0.000417	CcSEcCtD
Vandetanib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000109	0.000416	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000416	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000414	CcSEcCtD
Vandetanib—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.000414	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000412	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000409	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000409	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000107	0.000408	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000107	0.000408	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000408	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000408	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000407	CcSEcCtD
Vandetanib—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000106	0.000405	CcSEcCtD
Vandetanib—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000106	0.000404	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000402	CcSEcCtD
Vandetanib—Rash—Vincristine—peripheral nervous system neoplasm	0.000105	0.000402	CcSEcCtD
Vandetanib—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000105	0.000401	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.0004	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000399	CcSEcCtD
Vandetanib—Headache—Vincristine—peripheral nervous system neoplasm	0.000104	0.000399	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000397	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000396	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000394	CcSEcCtD
Vandetanib—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000103	0.000393	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000392	CcSEcCtD
Vandetanib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000101	0.000385	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000385	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000383	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	9.94e-05	0.00038	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	9.9e-05	0.000379	CcSEcCtD
Vandetanib—Nausea—Vincristine—peripheral nervous system neoplasm	9.89e-05	0.000378	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	9.87e-05	0.000378	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	9.85e-05	0.000377	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	9.72e-05	0.000372	CcSEcCtD
Vandetanib—Asthenia—Etoposide—peripheral nervous system neoplasm	9.68e-05	0.00037	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	9.65e-05	0.000369	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	9.65e-05	0.000369	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	9.59e-05	0.000367	CcSEcCtD
Vandetanib—Pruritus—Etoposide—peripheral nervous system neoplasm	9.54e-05	0.000365	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	9.51e-05	0.000364	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	9.49e-05	0.000363	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—peripheral nervous system neoplasm	9.4e-05	0.00036	CcSEcCtD
Vandetanib—Vomiting—Cisplatin—peripheral nervous system neoplasm	9.36e-05	0.000358	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	9.32e-05	0.000357	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	9.31e-05	0.000356	CcSEcCtD
Vandetanib—Rash—Cisplatin—peripheral nervous system neoplasm	9.28e-05	0.000355	CcSEcCtD
Vandetanib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	9.27e-05	0.000355	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	9.26e-05	0.000354	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	9.23e-05	0.000353	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	9.2e-05	0.000352	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	9.14e-05	0.00035	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	9.07e-05	0.000347	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	8.93e-05	0.000342	CcSEcCtD
Vandetanib—Dizziness—Etoposide—peripheral nervous system neoplasm	8.92e-05	0.000341	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	8.91e-05	0.000341	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.87e-05	0.000339	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	8.79e-05	0.000337	CcSEcCtD
Vandetanib—Nausea—Cisplatin—peripheral nervous system neoplasm	8.74e-05	0.000335	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	8.73e-05	0.000334	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	8.7e-05	0.000333	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	8.63e-05	0.00033	CcSEcCtD
Vandetanib—Vomiting—Etoposide—peripheral nervous system neoplasm	8.57e-05	0.000328	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	8.57e-05	0.000328	CcSEcCtD
Vandetanib—Rash—Etoposide—peripheral nervous system neoplasm	8.5e-05	0.000325	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—peripheral nervous system neoplasm	8.5e-05	0.000325	CcSEcCtD
Vandetanib—Headache—Etoposide—peripheral nervous system neoplasm	8.45e-05	0.000323	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	8.39e-05	0.000321	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	8.24e-05	0.000315	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	8.14e-05	0.000311	CcSEcCtD
Vandetanib—Cough—Epirubicin—peripheral nervous system neoplasm	8.08e-05	0.000309	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	8.08e-05	0.000309	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—peripheral nervous system neoplasm	8.03e-05	0.000307	CcSEcCtD
Vandetanib—Nausea—Etoposide—peripheral nervous system neoplasm	8.01e-05	0.000306	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—peripheral nervous system neoplasm	8e-05	0.000306	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—peripheral nervous system neoplasm	7.89e-05	0.000302	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	7.89e-05	0.000302	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—peripheral nervous system neoplasm	7.86e-05	0.000301	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	7.83e-05	0.0003	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	7.71e-05	0.000295	CcSEcCtD
Vandetanib—Oedema—Epirubicin—peripheral nervous system neoplasm	7.56e-05	0.000289	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	7.53e-05	0.000288	CcSEcCtD
Vandetanib—Infection—Epirubicin—peripheral nervous system neoplasm	7.51e-05	0.000287	CcSEcCtD
Vandetanib—Cough—Doxorubicin—peripheral nervous system neoplasm	7.48e-05	0.000286	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—peripheral nervous system neoplasm	7.43e-05	0.000284	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	7.41e-05	0.000284	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	7.4e-05	0.000283	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	7.4e-05	0.000283	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	7.34e-05	0.000281	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	7.3e-05	0.000279	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	7.3e-05	0.000279	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—peripheral nervous system neoplasm	7.27e-05	0.000278	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	7.25e-05	0.000277	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.000273	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000268	CcSEcCtD
Vandetanib—Infection—Doxorubicin—peripheral nervous system neoplasm	6.95e-05	0.000266	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	6.89e-05	0.000264	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	6.86e-05	0.000262	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	6.85e-05	0.000262	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—peripheral nervous system neoplasm	6.84e-05	0.000262	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	6.79e-05	0.00026	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	6.79e-05	0.00026	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	6.74e-05	0.000258	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	6.65e-05	0.000255	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	6.57e-05	0.000251	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	6.53e-05	0.00025	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—peripheral nervous system neoplasm	6.52e-05	0.000249	CcSEcCtD
Vandetanib—Pain—Epirubicin—peripheral nervous system neoplasm	6.46e-05	0.000247	CcSEcCtD
Vandetanib—Constipation—Epirubicin—peripheral nervous system neoplasm	6.46e-05	0.000247	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	6.37e-05	0.000244	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	6.33e-05	0.000242	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	6.28e-05	0.00024	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	6.24e-05	0.000239	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	6.18e-05	0.000237	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	6.16e-05	0.000236	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	6.08e-05	0.000233	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.04e-05	0.000231	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	6.03e-05	0.000231	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.000229	CcSEcCtD
Vandetanib—Pain—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.000229	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	5.98e-05	0.000229	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	5.98e-05	0.000229	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	5.72e-05	0.000219	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	5.53e-05	0.000212	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	5.53e-05	0.000212	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—peripheral nervous system neoplasm	5.42e-05	0.000208	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—peripheral nervous system neoplasm	5.35e-05	0.000205	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000198	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	5.02e-05	0.000192	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—peripheral nervous system neoplasm	5e-05	0.000191	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	4.95e-05	0.000189	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.81e-05	0.000184	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.79e-05	0.000183	CcSEcCtD
Vandetanib—Rash—Epirubicin—peripheral nervous system neoplasm	4.77e-05	0.000182	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.76e-05	0.000182	CcSEcCtD
Vandetanib—Headache—Epirubicin—peripheral nervous system neoplasm	4.74e-05	0.000181	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	4.63e-05	0.000177	CcSEcCtD
Vandetanib—Nausea—Epirubicin—peripheral nervous system neoplasm	4.49e-05	0.000172	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	4.45e-05	0.00017	CcSEcCtD
Vandetanib—Rash—Doxorubicin—peripheral nervous system neoplasm	4.41e-05	0.000169	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	4.41e-05	0.000169	CcSEcCtD
Vandetanib—Headache—Doxorubicin—peripheral nervous system neoplasm	4.38e-05	0.000168	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.15e-05	0.000159	CcSEcCtD
Vandetanib—FYN—Hemostasis—HRAS—peripheral nervous system neoplasm	8.98e-06	3.97e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PTPN11—peripheral nervous system neoplasm	8.91e-06	3.94e-05	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—AKT1—peripheral nervous system neoplasm	8.88e-06	3.92e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	8.83e-06	3.9e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.8e-06	3.89e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—ERBB2—peripheral nervous system neoplasm	8.77e-06	3.88e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—NRAS—peripheral nervous system neoplasm	8.76e-06	3.87e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.73e-06	3.86e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.6e-06	3.8e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—ERBB2—peripheral nervous system neoplasm	8.59e-06	3.79e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—MYC—peripheral nervous system neoplasm	8.59e-06	3.79e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.58e-06	3.79e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—ERBB2—peripheral nervous system neoplasm	8.55e-06	3.78e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTPN11—peripheral nervous system neoplasm	8.53e-06	3.77e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.49e-06	3.75e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.48e-06	3.75e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—ERBB2—peripheral nervous system neoplasm	8.46e-06	3.74e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KNG1—peripheral nervous system neoplasm	8.39e-06	3.71e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.38e-06	3.7e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.33e-06	3.68e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.29e-06	3.66e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HRAS—peripheral nervous system neoplasm	8.28e-06	3.66e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTPN11—peripheral nervous system neoplasm	8.22e-06	3.63e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.21e-06	3.63e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.21e-06	3.63e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.17e-06	3.61e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.17e-06	3.61e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—NRAS—peripheral nervous system neoplasm	8.14e-06	3.6e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	8.14e-06	3.6e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—ERBB2—peripheral nervous system neoplasm	8.1e-06	3.58e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—AKT1—peripheral nervous system neoplasm	8.09e-06	3.57e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.08e-06	3.57e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.08e-06	3.57e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.05e-06	3.56e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—AKT1—peripheral nervous system neoplasm	8.05e-06	3.56e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—AKT1—peripheral nervous system neoplasm	8.01e-06	3.54e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8e-06	3.53e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.99e-06	3.53e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—HRAS—peripheral nervous system neoplasm	7.97e-06	3.52e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.97e-06	3.52e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—HRAS—peripheral nervous system neoplasm	7.94e-06	3.51e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—AKT1—peripheral nervous system neoplasm	7.92e-06	3.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—HRAS—peripheral nervous system neoplasm	7.9e-06	3.49e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PTPN11—peripheral nervous system neoplasm	7.89e-06	3.48e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.88e-06	3.48e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	7.82e-06	3.45e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—peripheral nervous system neoplasm	7.81e-06	3.45e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—ERBB2—peripheral nervous system neoplasm	7.81e-06	3.45e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	7.8e-06	3.45e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.79e-06	3.44e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.76e-06	3.43e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	7.72e-06	3.41e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.71e-06	3.41e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.7e-06	3.4e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	7.65e-06	3.38e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	7.51e-06	3.32e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—HRAS—peripheral nervous system neoplasm	7.47e-06	3.3e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.45e-06	3.29e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.4e-06	3.27e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.36e-06	3.25e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.34e-06	3.24e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.32e-06	3.23e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—AKT1—peripheral nervous system neoplasm	7.31e-06	3.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—ERBB2—peripheral nervous system neoplasm	7.31e-06	3.23e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HRAS—peripheral nervous system neoplasm	7.3e-06	3.23e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTPN11—peripheral nervous system neoplasm	7.28e-06	3.22e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TH—peripheral nervous system neoplasm	7.26e-06	3.21e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.25e-06	3.2e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.21e-06	3.19e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.18e-06	3.17e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—ERBB2—peripheral nervous system neoplasm	7.16e-06	3.16e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.13e-06	3.15e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.11e-06	3.14e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	7.04e-06	3.11e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—AKT1—peripheral nervous system neoplasm	7.04e-06	3.11e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.04e-06	3.11e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.03e-06	3.1e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—AKT1—peripheral nervous system neoplasm	7.01e-06	3.1e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7e-06	3.09e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HRAS—peripheral nervous system neoplasm	6.98e-06	3.08e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—AKT1—peripheral nervous system neoplasm	6.98e-06	3.08e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.96e-06	3.07e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.92e-06	3.06e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—peripheral nervous system neoplasm	6.92e-06	3.06e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.85e-06	3.03e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.82e-06	3.01e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.76e-06	2.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—ERBB2—peripheral nervous system neoplasm	6.74e-06	2.98e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—HRAS—peripheral nervous system neoplasm	6.74e-06	2.98e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—HRAS—peripheral nervous system neoplasm	6.74e-06	2.98e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	6.73e-06	2.97e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.7e-06	2.96e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.7e-06	2.96e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	6.67e-06	2.95e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—HRAS—peripheral nervous system neoplasm	6.62e-06	2.92e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	6.6e-06	2.91e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—NRAS—peripheral nervous system neoplasm	6.53e-06	2.89e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.53e-06	2.88e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	6.5e-06	2.87e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	6.5e-06	2.87e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.46e-06	2.85e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.45e-06	2.85e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—AKT1—peripheral nervous system neoplasm	6.45e-06	2.85e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—NRAS—peripheral nervous system neoplasm	6.43e-06	2.84e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—HRAS—peripheral nervous system neoplasm	6.41e-06	2.83e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AKT1—peripheral nervous system neoplasm	6.35e-06	2.8e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.24e-06	2.76e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ERBB2—peripheral nervous system neoplasm	6.23e-06	2.75e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.16e-06	2.72e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	6.16e-06	2.72e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	6.11e-06	2.7e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.08e-06	2.69e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.08e-06	2.69e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.01e-06	2.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.98e-06	2.64e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.96e-06	2.63e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—peripheral nervous system neoplasm	5.95e-06	2.63e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—peripheral nervous system neoplasm	5.95e-06	2.63e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.94e-06	2.62e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NRAS—peripheral nervous system neoplasm	5.94e-06	2.62e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	5.92e-06	2.62e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.92e-06	2.61e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.87e-06	2.59e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—peripheral nervous system neoplasm	5.84e-06	2.58e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	5.81e-06	2.57e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.76e-06	2.54e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—ERBB2—peripheral nervous system neoplasm	5.75e-06	2.54e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	5.74e-06	2.54e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.72e-06	2.53e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.7e-06	2.52e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.67e-06	2.51e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.67e-06	2.5e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—peripheral nervous system neoplasm	5.66e-06	2.5e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.6e-06	2.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NRAS—peripheral nervous system neoplasm	5.56e-06	2.46e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.55e-06	2.45e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—peripheral nervous system neoplasm	5.53e-06	2.44e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.47e-06	2.42e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.46e-06	2.41e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NRAS—peripheral nervous system neoplasm	5.44e-06	2.41e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.36e-06	2.37e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	5.36e-06	2.37e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.28e-06	2.33e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.26e-06	2.32e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.15e-06	2.27e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NRAS—peripheral nervous system neoplasm	5.13e-06	2.27e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.12e-06	2.26e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.1e-06	2.25e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—peripheral nervous system neoplasm	5.07e-06	2.24e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.05e-06	2.23e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.04e-06	2.23e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.99e-06	2.21e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.96e-06	2.19e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NRAS—peripheral nervous system neoplasm	4.94e-06	2.18e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.94e-06	2.18e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	4.93e-06	2.18e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.9e-06	2.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	4.88e-06	2.16e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—peripheral nervous system neoplasm	4.78e-06	2.11e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—peripheral nervous system neoplasm	4.78e-06	2.11e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.77e-06	2.11e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	4.76e-06	2.1e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—peripheral nervous system neoplasm	4.74e-06	2.09e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.73e-06	2.09e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.72e-06	2.09e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.72e-06	2.09e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—peripheral nervous system neoplasm	4.71e-06	2.08e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	4.67e-06	2.06e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—peripheral nervous system neoplasm	4.61e-06	2.03e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.55e-06	2.01e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	4.51e-06	1.99e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.49e-06	1.98e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	4.47e-06	1.97e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.45e-06	1.97e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—peripheral nervous system neoplasm	4.38e-06	1.93e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—peripheral nervous system neoplasm	4.35e-06	1.92e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.33e-06	1.91e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.33e-06	1.91e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.31e-06	1.91e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	4.31e-06	1.9e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.29e-06	1.9e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.29e-06	1.89e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.22e-06	1.87e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—peripheral nervous system neoplasm	4.22e-06	1.86e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.22e-06	1.86e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	4.2e-06	1.86e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.17e-06	1.84e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	4.17e-06	1.84e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.16e-06	1.84e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—peripheral nervous system neoplasm	4.16e-06	1.84e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.14e-06	1.83e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.13e-06	1.83e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—peripheral nervous system neoplasm	4.08e-06	1.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—peripheral nervous system neoplasm	4.07e-06	1.8e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.03e-06	1.78e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.02e-06	1.78e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—peripheral nervous system neoplasm	3.98e-06	1.76e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	3.98e-06	1.76e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.97e-06	1.76e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	3.94e-06	1.74e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.94e-06	1.74e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.93e-06	1.74e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	3.92e-06	1.73e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	3.92e-06	1.73e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.87e-06	1.71e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—peripheral nervous system neoplasm	3.84e-06	1.69e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.79e-06	1.67e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—peripheral nervous system neoplasm	3.75e-06	1.66e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.66e-06	1.62e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.66e-06	1.62e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—peripheral nervous system neoplasm	3.62e-06	1.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.59e-06	1.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—peripheral nervous system neoplasm	3.59e-06	1.59e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—peripheral nervous system neoplasm	3.52e-06	1.55e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—peripheral nervous system neoplasm	3.47e-06	1.53e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.46e-06	1.53e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	3.46e-06	1.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.35e-06	1.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—peripheral nervous system neoplasm	3.31e-06	1.46e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.3e-06	1.46e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.23e-06	1.43e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.23e-06	1.42e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—peripheral nervous system neoplasm	3.2e-06	1.41e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	3.2e-06	1.41e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—peripheral nervous system neoplasm	3.19e-06	1.41e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.18e-06	1.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.16e-06	1.39e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	3.14e-06	1.39e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.09e-06	1.37e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.07e-06	1.35e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—peripheral nervous system neoplasm	3.06e-06	1.35e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.04e-06	1.34e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—peripheral nervous system neoplasm	2.95e-06	1.3e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.86e-06	1.26e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—peripheral nervous system neoplasm	2.83e-06	1.25e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.79e-06	1.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.75e-06	1.21e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.73e-06	1.21e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.69e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.65e-06	1.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.63e-06	1.16e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.59e-06	1.14e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.53e-06	1.12e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.34e-06	1.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.32e-06	1.03e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.24e-06	9.91e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.24e-06	9.88e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.98e-06	8.75e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	1.6e-06	7.06e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	8.63e-07	3.81e-06	CbGpPWpGaD
